Premium
P2‐016: Multicenter quantitative amyloid PET imaging in Phase III Alzheimer's therapeutic trials: Strategies for achieving good imaging practices in the support of drug development
Author(s) -
P. Seibyl John,
Zubal George,
Tamagnan Gilles,
Marek Kenneth
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.325
Subject(s) - clinical trial , drug development , medicine , medical physics , neuroimaging , standardization , nuclear medicine , computer science , pathology , drug , pharmacology , psychiatry , operating system
including the N100, P100, N200, P300, P400, P600, a difference wave at 700ms, and also behavioral responses (d’ measures). First, each variable was assessed individually in binary logistic regression analyses, and sensitivity and specificity profiles were constructed. Next, the best performers in terms of sensitivity and specificity were entered into regression analyses in pairs, and then in groups of three. Results: Good discrimination was achieved by several combinations of 3 variables, with sensitivity ranging from 76.2% to 77.8%, and specificity from 87.7% to 90.4%. Brain source estimation (GeoSource) showed that the frontal P400, which participated in several good classification outcomes, is generated in the left hippocampus. Conclusions: The combination of multiple cognitive evoked potential components achieved a good sensitivity/specificity profile. Further, the association of hippocampal function with task performance suggests that cognitive evoked potentials may reflect fundamental aspects of the pathophysiology of AD. Taken together, these results support the development of cognitive evoked potentials as functional biomarkers in AD.